Aardvark Therapeutics, Inc.
AARD
$4.18
-$0.36-7.93%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 16.97M | 13.79M | 10.77M | 7.83M | 7.17M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 74.72M | 62.73M | 53.47M | 40.86M | 31.08M |
| Operating Income | -74.72M | -62.73M | -53.47M | -40.86M | -31.08M |
| Income Before Tax | -69.87M | -57.59M | -48.77M | -36.64M | -27.72M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -69.87 | -57.59 | -48.77 | -36.64 | -27.72 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -69.87M | -57.59M | -48.77M | -36.64M | -27.72M |
| EBIT | -74.72M | -62.73M | -53.47M | -40.86M | -31.08M |
| EBITDA | -74.68M | -62.69M | -53.44M | -40.83M | -31.07M |
| EPS Basic | -3.21 | -2.93 | -4.28 | -4.58 | -5.29 |
| Normalized Basic EPS | -2.01 | -1.83 | -2.67 | -2.84 | -3.29 |
| EPS Diluted | -3.21 | -2.93 | -4.28 | -4.58 | -5.29 |
| Normalized Diluted EPS | -2.01 | -1.83 | -2.67 | -2.84 | -3.29 |
| Average Basic Shares Outstanding | 87.00M | 78.38M | 60.66M | 42.94M | 25.21M |
| Average Diluted Shares Outstanding | 87.00M | 78.38M | 60.66M | 42.94M | 25.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |